Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XTAMPZA ER vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full mu-opioid receptor agonist, producing analgesia, euphoria, and sedation. Xtampza ER utilizes DETERx technology to provide extended-release properties and resist tampering.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Relief of moderate to moderately severe pain
Initial: 9 mg orally every 12 hours with food; titrate by 9 mg every 3-7 days as needed; maximum dose: 36 mg every 12 hours.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
3-4 hours for immediate-release morphine; 8-12 hours for extended-release formulation (XTAMPZA ER), allowing twice-daily dosing
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP3A4 and CYP2D6 to active and inactive metabolites.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Primarily renal (70-90% as morphine-3-glucuronide, morphine-6-glucuronide, and free morphine); biliary/fecal (10-20%)
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
20-35% bound to albumin
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
1-4 L/kg; high Vd indicates extensive tissue distribution (muscle, kidney, liver, lungs)
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Oral: 30-40% (first-pass metabolism reduces systemic availability; XTAMPZA ER uses Cydot technology to enhance absorption and reduce food effect)
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
GFR 30-59 m L/min: reduce dose by 25% and titrate cautiously; GFR <30 m L/min: contraindicated or avoid use due to accumulation of naltrexone metabolite.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Child-Pugh Class A or B: no adjustment recommended; Child-Pugh Class C: avoid use (no studies).
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Not approved for patients <18 years of age.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Start at low end of dosing range (9 mg every 12 hours); titrate slowly due to increased sensitivity and potential for respiratory depression.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; opioid risk evaluation and mitigation strategy (REMS).
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion,Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Opioid-induced hyperalgesia,Gastrointestinal effects (e.g., constipation, ileus),Adrenal insufficiency,Severe hypotension,Seizures,Use in patients with increased intracranial pressure or head injury
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to oxycodone or any component of the formulation
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase oxycodone levels, potentiating toxicity. High-fat meals may delay absorption but do not alter overall exposure significantly. Alcohol should be strictly avoided as it can increase CNS depression and risk of respiratory depression.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
Pregnancy category C. First trimester: Potential for neural tube defects and other major malformations, though data limited. Second and third trimesters: Prolonged use may lead to neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Risk of preterm labor, low birth weight, and fetal growth restriction with chronic use.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Excreted in human milk; M/P ratio not reported. Monitor infant for respiratory depression, sedation, and withdrawal symptoms. Use caution, especially with high maternal doses or prolonged use. Breastfeeding generally not recommended due to risk of infant toxicity.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
Pregnancy may alter pharmacokinetics due to increased hepatic metabolism, renal clearance, and plasma volume expansion. Lower AUC and Cmax expected; consider dose adjustments based on pain severity, but avoid abrupt discontinuation to prevent withdrawal. No standard dose recommendations; titrate to effect with caution.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
XTAMPZA ER is an extended-release formulation of oxycodone designed to be taken once daily. It uses a polymer matrix to provide prolonged absorption. Do not crush, chew, or dissolve the capsules, as this can lead to rapid release and potential fatal overdose. Due to its high drug load, it is not interchangeable with other oxycodone ER products. Initiate with caution in opioid-naive patients; consider lower starting doses. Monitor for respiratory depression, especially during initiation and titration. Use with CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin) requires dose adjustment. Abuse-deterrent properties are limited; caution in patients with history of substance abuse.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Swallow the capsule whole; do not crush, chew, or dissolve it.,Avoid alcohol while taking this medication; it can increase the risk of dangerous side effects.,Do not stop abruptly; work with your doctor to taper the dose to avoid withdrawal symptoms.,Store safely out of reach of children and pets; dispose of unused medication via a take-back program.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Report any breathing difficulty, severe constipation, or signs of overdose (e.g., extreme sleepiness, slow heartbeat).
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XTAMPZA ER vs ANEXSIA, answered by our medical review team.
XTAMPZA ER is a Opioid Analgesic that works by Oxycodone is a full mu-opioid receptor agonist, producing analgesia, euphoria, and sedation. Xtampza ER utilizes DETERx technology to provide extended-release properties and resist tampering.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XTAMPZA ER and ANEXSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XTAMPZA ER is: Initial: 9 mg orally every 12 hours with food; titrate by 9 mg every 3-7 days as needed; maximum dose: 36 mg every 12 hours.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XTAMPZA ER and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XTAMPZA ER is classified as Category C. Pregnancy category C. First trimester: Potential for neural tube defects and other major malformations, though data limited. Second and third trimesters: Prolonged use may lead to . ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.